Neurocrine’s $2.9 Billion Bet: A Strategic Move Into Rare Diseases In a major move that could reshape its future, Neurocrine Biosciences has…
Gilead Strikes $7.8 Billion Deal for Arcellx in Bold Cancer Therapy Bet
3 Mins read
The biotech giant announced it will acquire its partner Arcellx in a deal worth up to $7.8 billion. The acquisition significantly expands…
Novartis Drops $12 Billion on Biotech Firm — Could This Be the Biggest Medical Breakthrough Yet?
1 Mins read
Novartis Makes a Stunning $12 Billion Move Swiss pharmaceutical giant Novartis has announced it will acquire U.S. biotech company Avidity Biosciences for…
